Harnessing jumping genes to advance gene-therapy cancer treatment

PlasmidFactory partnership to continue

21-Jan-2020 - In an effort to optimize the Sleeping Beauty system, the MDCell – Helmholtz Innovation Lab is extending its collaboration with PlasmidFactory. If you want to modify a human body’s immune cells – for example by giving them new vitality to fight a tumor or stop an autoimmune disease – you need safe ...

PlasmidFactory is now part of a German AAV Network

09-May-2018 - PlasmidFactory GmbH & Co. KG announces that the company will join forces with three other companies regarding adeno-associated virus (AAV) vector manufacturing. SIRION Biotech possesses one of the world’s most comprehensive viral vector engineering platforms, Vibalogics offers process ...

PlasmidFactory expands lab capacities

30-Apr-2018 - PlasmidFactory GmbH & Co. KG announces that it has acquired new laboratory space for research and development as well as for the highly documented production of plasmid DNA, and has begun reconstructing and equipping the same. "New capabilities are the key to helping our customers move to ...

Cancer-fighting gene therapy

Technology transfer project at the MDC

12-May-2016 - The Max Delbrück Center for Molecular Medicine (MDC), part of the Helmholtz Association, has announced a cooperation project between two MDC research groups and three industry partners: the ‘Max Delbrück Center Cell Engineering Lab’ (MD-CEL). Their joint goal is to develop a cell-based gene ...

PlasmidFactory: New production facility successfully put into operation

Plasmid DNA for the most exacting requirements

14-Jun-2011 - PlasmidFactory's new facility for the production of high purity plasmid DNA is now operating successfully in new, modern labs. Plasmid DNA of the highest quality is being produced in the new premises in accordance with the EMEA guideline CHMP/BWP/2458/03. To ensure product safety, substances of ...

IMAGNA project team started work on therapeutic vaccination against cat fibrosarcoma

24-Sep-2007 - IMAGNA (immuno gene therapy with magnetic nanoparticles) has been founded by members of the Inst. of Experimental Oncology Klinikum rechts der Isar (Technical University Munich), the Clinic of Small Animal Medicine of the Ludwig-Maximilians-Universität , Bayer Schering Pharma AG, chemicell GmbH, ...

PlasmidFactory obtained worldwide license from DKFZ for manufacture of pDG helper/packaging vectors

16-Feb-2007 - PlasmidFactory has obtained a worldwide license from the German Cancer Research Center DKFZ for the manufacture and the marketing of the pDG helper/packaging vector series used for adeno-associated virus (AAV) production. The license agreement extends to multiple vector serotypes such as pDG, ...